Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

VolitionRx touts promising cancer detection data, but commercial impact remains unproven.

Risk flags

• ●Commercialization risk is high, as there are no signed agreements, regulatory milestones, or disclosed sales; the company is only in discussions and technical evaluations. Without concrete commercial traction, the pathway to revenue remains speculative.
• ●Financial transparency is poor; the announcement omits all financial performance data, making it impossible to assess cash burn, runway, or profitability. This lack of disclosure limits investor ability to gauge financial health or near-term funding needs.
• ●Execution risk is significant, given the reliance on small-cohort validation data and the absence of large-scale, independent studies. Scaling from promising technical results to clinical adoption and commercial success is a multi-year, uncertain process.
• ●Market size claims are unsubstantiated and presented without supporting methodology or evidence of addressable share. Relying on these figures for investment decisions is risky, as they do not reflect actual market access or competitive positioning.
• ●The announcement uses promotional language to inflate the perceived impact of routine milestones, such as patent filings and technical evaluations, which do not guarantee future success or adoption.

Bottom line

This announcement signals technical progress for VolitionRx Limited’s liquid biopsy technology, but lacks any evidence of commercial traction, regulatory advancement, or financial performance. The company’s claims about large addressable markets and ongoing partnership discussions are aspirational and not backed by signed deals or disclosed revenue. The technical results are promising but limited to small cohorts, with no timeline or pathway to near-term value realization. Investors should treat the commercial potential as unproven until larger, independent validation studies and concrete business milestones are disclosed. The most important takeaway is that while the science is advancing, the investment case remains speculative and unsupported by financial or commercial data.

Announcement summary

(NYSE: VNRX) VolitionRx Limited announced the publication of the first peer-reviewed paper describing its technology for isolating and analyzing >99% pure circulating tumor-derived DNA (ctDNA). The company is in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of its "Capture-Seq™" technology and is undertaking technical evaluations with potential licensors. Volition estimates a Total Addressable Market on an annualized basis of approximately $23 billion for the human Multi-Cancer Early Detection (MCED) use and over $13 Billion for Minimum Residual Disease (MRD). In two independent cohorts, the technology detected 49/49 cancers in the first cohort and 13/14 later stage cancers in a second blinded cohort, with no false positives reported. Data from a blinded validation cohort of 81 subjects showed early-stage cancer detection of 95% of stage I and II cancers. The company is fast-tracking the development of Capture-Seq™, conducting further studies, and has filed a number of new patents to protect this technology. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

Disagree with this article?